Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study.,The Lancet

当前位置： X-MOL 学术 › Lancet › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study.
The Lancet ( IF 98.4 ) Pub Date : 2018-Feb-01 , DOI: 10.1016/s1470-2045(18)30011-1
Hagop Kantarjian ₁ , Farhad Ravandi ₁ , Nicholas J Short ₁ , Xuelin Huang ₂ , Nitin Jain ₁ , Koji Sasaki ₁ , Naval Daver ₁ , Naveen Pemmaraju ₁ , Joseph D Khoury ₃ , Jeffrey Jorgensen ₃ , Yesid Alvarado ₁ , Marina Konopleva ₁ , Guillermo Garcia-Manero ₁ , Tapan Kadia ₁ , Musa Yilmaz ₁ , Gautam Bortakhur ₁ , Jan Burger ₁ , Steven Kornblau ₁ , William Wierda ₁ , Courtney DiNardo ₁ , Alessandra Ferrajoli ₁ , Jovitta Jacob ₁ , Rebecca Garris ₁ , Susan O'Brien ₄ , Elias Jabbour ₁

Affiliation

Inotuzumab ozogamicin, an anti-CD22 monoclonal antibody bound to a toxin, calicheamicin, has shown single-agent activity in relapsed or refractory acute lymphoblastic leukaemia. We aimed to assess the activity and safety of inotuzumab ozogamicin in combination with low-intensity chemotherapy in older patients with acute lymphoblastic leukaemia.

中文翻译：

Inotuzumab ozogamicin 联合低强度化疗治疗费城染色体阴性急性淋巴细胞白血病老年患者：一项单臂 2 期研究。

Inotuzumab ozogamicin 是一种与毒素加利车霉素结合的抗 CD22 单克隆抗体，已在复发性或难治性急性淋巴细胞白血病中显示出单药活性。我们的目的是评估伊珠单抗奥佐米星与低强度化疗联合治疗老年急性淋巴细胞白血病患者的活性和安全性。

更新日期：2018-02-01

点击分享查看原文

点击收藏

阅读更多本刊最新论文